Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
Toke Bek, Sidsel Ehlers Klug Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark Purpose: Randomized clinical trials studying the effects of VEGF inhibition on wet age-related macular degeneration (wAMD) are designed so that the effects of individually varying risk factors on...
Guardado en:
Autores principales: | Bek T, Klug SE |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8565da7e1e9445d1ae5fdb9db90e2457 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
por: Iida T, et al.
Publicado: (2016) -
The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
por: Varano M, et al.
Publicado: (2016) -
Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
por: Veluswamy B, et al.
Publicado: (2020) -
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019) -
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018)